Top Injectable Manufacturer in Maldives – Reliable Pharmaceutical Solutions
Last Updated: September 14, 2026
TL;DR: The Maldives Food and Drug Authority publishes a named list of Reference Regulatory Authorities in Annexure-I of its Guideline on Good Reliance Practice. We read all 45 entries and India is not among them, though MFDA itself describes the list as dynamic and subject to change. Reliance pathways are mandatory for parenterals; a WHO-GMP certificate issued by an Indian state licensing authority is not one of the enumerated grounds for exempting a foreign site from inspection; and the licence that can stop a shipment sits on the Maldivian importer's registered medicine warehouse.
Key Takeaways
MFDA publishes its reference list as Annexure-I to its Guideline on Good Reliance Practice, verified on 18 July 2024. We read all 45 entries and India is not among them, though section 6.3.1 calls the annexure a dynamic list subject to change. A second annexure, Annex II of the 176-page registration guideline, we did not reach, so the two must be kept apart.
Section 6.3.4 of the registration guideline makes reliance pathways mandatory for high-risk products "like parenteral", so on that wording a sterile injectable cannot elect the full-dossier route as of right.
On the exemption criteria we read in section 10.1.1, an Indian state licensing authority's WHO-GMP certificate is not among the grounds for exempting a foreign site from inspection.
The binding constraint is the Maldivian importer's registered medicine warehouse — a minimum of 200 square feet on MFDA's import guideline, inspected, MVR 1,200 to register — and if renewal is not filed before expiry the warehouse "shall be removed from the Authorized Importers List".
Introduction: What an Injectable Manufacturer in Maldives Must Clear First
MFDA states the market's basic condition in its own import guideline: "Due to inadequate capacity to manufacture, Maldives is a 100% importing country with regard to medicine." WHO's 2025 pharmaceutical country profile records the number of private pharmaceutical manufacturers in the Maldives as "None". Every vial of a sterile injectable reaching a Maldivian hospital has crossed a border first, so whose regulatory decisions MFDA will lean on is an opening question for an exporter.
That question has a published answer. MFDA publishes its Reference Regulatory Authorities in Annexure-I of its Guideline on Good Reliance Practice for Regulation of Medicines, a document its Medicine and Therapeutic Goods Technical Committee verified on 18 July 2024. We read that annexure in full: 45 numbered entries, spanning Australia, Canada, Japan, Singapore, Switzerland, the United Kingdom, the United States and much of the European Union and EEA. India is not among the 45 entries we counted, and the Central Drugs Standard Control Organisation is not named anywhere in that annexure. MFDA describes the annexure, in section 6.3.1, as "a dynamic list and is subject to change by MFDA as needed", so India's absence describes the document we read in September 2026 rather than the one that will exist later.
What Sets a World-Class Injectable Manufacturer in Maldives Apart
The practical work sits in section 10.1.1 of MFDA's Guideline on Good Reliance Practice, which governs GMP verification for a site outside the Maldives. Importers are "exempted for inspection of manufacturing unit abroad" if the product qualifies under a listed set of criteria. Those we read include registration with a Reference Regulatory Authority in Annexure-I; registration with at least three of the authorities the clause calls "former Eastern Europe"; a GMP certificate retrievable on the EUDRA-GMDP website; a WHO-prequalified product together with the facility that makes it; and a product approved by, or a site inspected by, a PIC/S Participating Authority.
India is not a PIC/S participating authority and CDSCO does not appear on the Annexure-I list we read, so a WHO-GMP certificate issued by an Indian state licensing authority is not, on the face of those criteria, one of the enumerated exemption routes. The certificate remains part of the evidence package, but no clause we read treats it, on its own, as a ground for exempting the site from inspection. MFDA operates a risk-based exemption rather than a blanket exclusion and reserves its position expressly, providing that it "may conduct risk based GMP inspection of the manufacturing facility any time (before or after grant of approval)".
Quality Systems Behind Every Sterile Injectable — and the Zone IVA Question
MFDA names a climatic zone, and the zone it names is IVA rather than IVb. Its Guideline on Good Reliance Practice provides at section 7.1.2 that reliance on a Reference Regulatory Authority's assessment is subject to the availability of quality data "pertaining to Zone IVA conditions (if required)", and at section 9.1(a) that stability studies should be "as per Zone IVA (for pharmaceutical)". Where Zone IVA data are not available, the same clause asks for a commitment and protocol for studies under the appropriate climatic conditions.
The 176-page registration guideline enumerates the ICH zones from I to IVB but, in the portion we read, does not assign the Maldives to any one of them. We searched the WHO and ICH text of the Q1F stability guideline for "Maldives" and found no occurrence, so we found no table that names the Maldives and assigns it a zone. The statement we can support is the narrower and more useful one: MFDA's own reliance guideline asks for Zone IVA data by name. ISO Class 5 filling, HPLC and GC assay, LAL endotoxin testing and Karl Fischer water determination are the capabilities that make that evidence possible to assemble; they are not themselves the gate.
Working out whether the Maldives is reachable for your product? Talk to our regulatory team
Why Farbe Firma Is the Trusted Injectable Manufacturer in Maldives for Global Buyers
Start with who holds the registration, because it is not the foreign manufacturer. Every application under the registration guideline's table must carry a Letter of Appointment together with a letter from the manufacturer to MFDA, and that appointment is how a Maldivian party takes on the manufacturer's responsibilities for the product. On our reading of the Dhivehi text of Medicine Regulation R-64/2026, Article 11(b) provides that only a Maldivian citizen or a legal person with Maldivian shareholding may submit a registration application. We found no official English translation, so that reading should be confirmed with MFDA before it is relied on commercially.
Then the licence that can actually stop a shipment. MFDA's Guideline for Authorization of Medicine Import, issued 23 June 2022, makes a registered medicine warehouse the prerequisite for an import licence, with applications running through the Dhirithi Portal and the guideline stating that "the floor area of a medicine warehouse shall be minimum 200 square feet." The renewal rule belongs in a partner agreement: if a renewal request has not been submitted before the permit expires, the warehouse "shall be removed from the Authorized Importers List" and the importer files a fresh application rather than a renewal.
Registration is necessary and not sufficient, and the last gate is commercial. WHO's 2025 profile records public-sector procurement as centralized, naming the State Trading Organization for public-sector pharmacies and the Ministry of Health for hospital-use medicines. MFDA's Approved Drug List then divides the market again: its legend reserves some products to national programmes or to designated importers, and marks others as restricted to hospital and institutional use, which "cannot be kept for sale in pharmacies" — so being on the list does not by itself establish who may buy. As a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, exporting to more than 30 countries and working in CTD and ACTD format, what Farbe Firma contributes is evidence a Maldivian partner can file: batch documentation, stability data referable to Zone IVA, and change control that survives an inspection request arriving after approval.
Explore Farbe Firma: Products / Global Reach / About Us
Frequently Asked Questions (FAQ)
Is India on the Maldives Food and Drug Authority's reference list?
Not on the list we read. MFDA publishes its Reference Regulatory Authorities as Annexure-I to its Guideline on Good Reliance Practice, verified on 18 July 2024, and India is not among the 45 entries we counted, nor is CDSCO named in that annexure. Two qualifications: section 6.3.1 describes the annexure as a dynamic list subject to change, and a second annexure, Annex II of the 176-page registration guideline, is pointed at by a different MFDA document that our extraction did not reach.
Does the Maldives accept the Indian Pharmacopoeia?
Section 11.2(e)(i) of the registration guideline requires every ingredient to be listed with its pharmacopoeial standard, "i.e., British pharmacopeia (BP), US pharmacopeia (USP) or Indian pharmacopeia (IP) or any pharmacopeia of stringent regulatory authorities". That is acceptance of IP as a book of standards against which a specification may be written. Recognition of a pharmacopoeia is not recognition of the agency that publishes it, and nothing in that clause places India on a reliance pathway. MFDA's own documents also expand IP differently — "Indian pharmacopeia" in one guideline, "International Pharmacopoeia" in the other.
Is a WHO-GMP certificate enough for MFDA to accept an Indian manufacturing site?
Not on its own, on the criteria we read. Section 10.1.1 of the reliance guideline enumerates the grounds for exempting a foreign manufacturing unit from inspection, and an Indian state licensing authority's WHO-GMP certificate is not among them. The routes that remain visibly open are WHO prequalification of the product together with the facility that makes it, inspection by a PIC/S participating authority, registration with at least three of the authorities the clause calls former Eastern Europe, a qualifying inspection by another NRA within three years, or an MFDA inspection of the site itself.
Which regulation governs a Maldivian registration filed today?
That is a question to put to MFDA in writing, because the answer is changing. Medicine Regulation R-64/2026 was gazetted on 25 July 2026 and MFDA's download page states that it takes effect 90 days later, on 23 October 2026, so as at September 2026 it is published but not commenced. MFDA's operative guidelines still cite R-46/2014 and amendment R-49/2016, while its Laws and Regulations download category offers only R-64/2026. Article 72 of R-64/2026 is headed with the Dhivehi for regulations repealed, but we could not read the instruments it names.
What does a Maldivian partner actually need in place?
A registered medicine warehouse and a current entry on the Authorized Importers List, which MFDA's import guideline says is published every four months. The warehouse is inspected, the guideline states a minimum floor area of 200 square feet, and registration or re-registration is invoiced at MVR 1,200.
Technically Reviewed By: Maulik Sudani & Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote / View Products / FAQ / Blog
Comments